Hm Payson & CO Immuno Gen, Inc. Transaction History

Hm Payson & CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 06, 2023	SELL	$14.09 - $19.87 $47,328 - $66,743	-3,359 Reduced 80.57%	810 $12,000
Q2 2023 Jul 17, 2023	BUY	$3.75 - $20.05 $12,596 - $67,347	3,359 Added 414.69%	4,169 $78,000
Q2 2019 Aug 15, 2019	BUY	$1.8 - $3.3 $1,458 - $2,673	810 New	810 $2,000
Q1 2019 Jul 31, 2019	SELL	$2.41 - $5.91 $1,952 - $4,787	-810 Closed	0 $0
Q4 2018 Feb 15, 2019	BUY	$3.94 - $9.7 $3,191 - $7,856	810 New	810 $4,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Hm Payson & CO, based on Form 13F filings with the SEC.

Stay updated on Hm Payson & CO with notifications on news.